Evidence map›Paper›PMID 33587103›Full record

ArticleRheumatology (Oxford, England)2021

Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews.

Anna-Maria Hoffmann-Vold, Elisabeth Bendstrup, Theodoros Dimitroulas, Roger Hesselstrand, Antonio Morais, Ritva Peltomaa, Vanessa Smith, Joep Welling, Madelon C Vonk, Wim A Wuyts

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 9 countries.

Anna-Maria Hoffmann-VoldDepartment of Rheumatology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-6467-7422
Elisabeth BendstrupDepartment of Respiratory Disease and Allergy, Centre for Rare Lung Diseases, Aarhus University Hospital, Aarhus, Denmark.
Theodoros DimitroulasFourth Department of Internal Medicine, Hippokration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0002-0364-1642
Roger HesselstrandSection of Rheumatology, Department of Clinical Sciences, Skåne University Hospital, Lund, Sweden.
Antonio MoraisDepartment of Pulmonology Centro Hospitalar, Universitário de São João, Faculdade de Medicina do Porto, Porto, Portugal.
Ritva PeltomaaDepartment of Rheumatology, Helsinki University Hospital, Helsinki, Finland.
Vanessa SmithDepartment of Internal Medicine, Ghent University; Department of Rheumatology, Ghent University Hospital; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Centre (IRC), Gent, Belgium.ORCID 0000-0001-6271-7945
Joep WellingFESCA Federation of European Scleroderma Associations, NVLE, Utrecht.
Madelon C VonkDepartment of Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Wim A WuytsDepartment of Pulmonology, University Hospitals Leuven, Leuven, Belgium.
Aarhus University Hospital · DKAristotle University of Thessaloniki · GRGhent University Hospital · BEHelsinki University Hospital · FIHospital de São João · PTKU Leuven · BEOslo University Hospital · NORadboud University Nijmegen · NLScleroderma Foundation · USSkåne University Hospital · SE

Funding

Boehringer Ingelheim
6 · The paper itself

Abstract

objectivesInterstitial lung disease is frequent in SSc (SSc-ILD) and associates with significantly reduced quality of life. Here we aimed to analyse patient pathways, and experiences of patients and healthcare providers (HCPs) in order to identify unmet needs in the management of SSc-ILD patients.

methodsSemi-structured qualitative interviews conducted in eight European countries looked at HCP (n = 95) and patient perspectives (n = 47) using two sets of 70 research questions. Pre-diagnostic, diagnostic and post-diagnostic phases of the patient pathway were systematically explored.

results(i) In the pre-diagnostic phase several gaps were identified by HCPs and patients in all participating countries: limited disease knowledge among primary care physicians and specialists, lack of accurate patient information, and delayed and/or inappropriate referral. (ii) The diagnostic phase is in most countries coordinated by rheumatologists, who are also the main point of care. Depending on the local health system, organization of multidisciplinary collaboration varies. HCPs issued lack of national guidelines, while patients stated difficulties obtaining disease-related information. (iii) In the post-diagnostic phase, HCPs and patients indicated lack of curative treatment, specialized nurses, and paramedical  and psychological support. Patients and caregivers additionally expressed the need for clear information on SSc-ILD.

conclusionLack of disease specific knowledge, gaps in national healthcare systems and insufficient information and support for patients and caregivers were identified as unmet needs to ensure timely diagnosis, provide better patient management and to improve quality of life in SSc-ILD patients.

Indexed as

CaregiversDisease ManagementDelivery of Health CareHealth Services Needs and DemandHumansLung Diseases, InterstitialQuality of LifeRetrospective StudiesScleroderma, Systemicdiagnosisexpert opinioninterstitial lung diseaseinterviewmanagementsystemic sclerosis

Identifiers

PMID33587103
PMCPMC8788003
OpenAlexW3130261012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.